Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

BICALUTAMIDE

All products: not a benefit

Other products in the same Health Canada class (L02B, L02BB) — coverage varies; not interchangeable

  • Flutamide (Euflex): general benefit, Not a benefit
  • Enzalutamide (Xtandi): not a benefit
  • Abiraterone (Zytiga): general benefit
  • Anastrozole (Arimidex): general benefit
  • Degarelix (Firmagon): general benefit
  • Exemestane (Aromasin): general benefit

3 more in the class list below

Casodex · DIN 02184478 · 50mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2025-03-07 — choose a marketed DIN from the same-category list.Discontinued 2025-03-07 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2025-03-07 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2025-03-07 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Casodex (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
Savings card: RxHelp ONE lists CASODEX (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
Limit of one Prescription Drug Card Program / Patient Financial Assistance Card from any adjudicator per DIN and claim submitted. The RxHelpONE card CANNOT be combined with any other card or offer. (Terms of Use) (rxhelp.ca, Sep 10, 2026 ↗)
1 brand, same coverage
Casodex · DIN 02184478 Manufacturer: AstraZeneca; listing date 1996-12-19 Health Canada: Cancelled post market since 2025-03-07 · brand CASODEX · ATC L02BB03 BICALUTAMIDE · form Tablet · route Oral · ingredients BICALUTAMIDE 50 MG · company Astrazeneca canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Casodex: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19647 · Verify on the e-Formulary ↗ (DIN 02184478)

Source record
DIN 02184478: Casodex Raw flags: notABenefit=Y, sec3=Y Item: 100000108; group id 145; item number 0244; lccId None; manufacturer id AZC Source form: Tab; strength: 50mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02184478 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19647
Interchangeable products
Apo-Bicalutamide · DIN 02296063 · $1.2690 Bicalutamide · DIN 02519178 · $1.2690 Bicalutamide Tablets · DIN 02325985 · $1.2690 Co Bicalutamide · DIN 02274337 · $1.2690 Jamp-Bicalutamide · DIN 02357216 · $1.2690 PMS-Bicalutamide · DIN 02275589 · $1.2690 Ran-Bicalutamide · DIN 02371324 · $1.2690 Teva-Bicalutamide · DIN 02270226 · $1.2690
Shortage status: discontinued (2025-02-06, reported by ASTRAZENECA CANADA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02184478
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2025-03-07 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (10:00 ANTINEOPLASTIC AGENTS) and how they are covered

Matched class: 10:00 ANTINEOPLASTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABIRATERONE ACETATE, ALTRETAMINE, ANASTROZOLE, BUSERELIN ACETATE, BUSULFAN, CAPECITABINE, CHLORAMBUCIL, CYPROTERONE ACETATE, DAUNORUBICIN, DEGARELIX ACETATE, ETOPOSIDE, EXEMESTANE, FLUOROURACIL & SALICYLIC ACID, FULVESTRANT, GOSERELIN ACETATE, HYDROXYUREA, IMATINIB MESYLATE, LETROZOLE, LEUPROLIDE ACETATE, MELPHALAN, MERCAPTOPURINE, MITOTANE, PROCARBAZINE HCL, TEMOZOLOMIDE, THIOGUANINE, TRIPTORELIN PAMOATE Some products covered without a code (check the product listing): CYCLOPHOSPHAMIDE, FLUTAMIDE, LOMUSTINE (CCNU), MEGESTROL ACETATE, METHOTREXATE, TAMOXIFEN CITRATE, VINCRISTINE SULFATE 10:00 ANTINEOPLASTIC AGENTS

FLUTAMIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 250mg · Tab

ENZALUTAMIDE

· 5 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 40mg · Cap

ABIRATERONE ACETATE

· 18 products · General benefit · strengths: 250mg, 500mg · Tab

ANASTROZOLE

· 17 products · General benefit · strengths: 1mg · Tab

DEGARELIX ACETATE

· 2 products · General benefit · strengths: 80mg, 120mg · Pd for Inj-Vial Pk

EXEMESTANE

· 3 products · General benefit · strengths: 25mg · Tab

FULVESTRANT

· 6 products · General benefit · strengths: 50mg/mL · Inj Sol

LETROZOLE

· 20 products · General benefit · strengths: 2.5mg · Tab

TAMOXIFEN CITRATE

· 8 products · General benefit (4), Listed, not a benefit (4) · strengths: 10mg, 20mg · Tab

ALTRETAMINE

· 1 products · General benefit · strengths: 50mg · Cap

BUSERELIN ACETATE

· 4 products · General benefit · strengths: 6.3mg, 9.45mg, 1mg/mL · Implant Kit, Inj Sol-5.5mL Pk, Nas Sp-10mL Pk

BUSULFAN

· 1 products · General benefit · strengths: 2mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 10:00 and 34 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE TEVA-BICALUTAMIDE (bicalutamide) 50 mg is indicated for use in combination therapy with either a luteinizing hormone releasing hormone (LHRH) analogue or surgical castration in the treatment of metastatic (Stage D2) prostate cancer. Pediatrics: The safety and effectiveness of bicalutamide in children has not been established. https://pdf.hres.ca/dpd_pm/00041652.PDF PM date: September 27, 2017 Source product: TEVA-BICALUTAMIDE; DIN 02270226; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Casodex · DIN 02184478 Shortage status: discontinued (2025-02-06, reported by ASTRAZENECA CANADA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02184478

Check this DIN again

Other review policies

For Casodex: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026